IL-8/CXCL8 Protein, Cynomolgus, Recombinant (His)

Interleukin-8 (IL-8) has been revealed as a critical regulator of CNS function and development with participation in many CNS disorders including gliomas.Several promising approaches that target directly or indirectly IL-8 effects in gliomas are currently in progress while more-in-depth studies are needed to validate its biomarker role and elucidate the underlying molecular mechanisms.

规格	价格/CNY		数量
100 μg	￥ 3,100	5日内发货
500 μg	￥ 12,400	5日内发货
1 mg	￥ 20,700	5日内发货

规格

价格/CNY

货期

数量

100 μg

￥ 3,100

5日内发货

500 μg

￥ 12,400

5日内发货

1 mg

￥ 20,700

5日内发货

生物活性	Immobilized Cynomolgus IL-8, His Tag at 0.5μg/ml (100μl/well) on the plate. Dose response curve for Anti-IL-8 Antibody, hFc Tag with the EC50 of 13.0ng/ml determined by ELISA.
产品描述	Interleukin-8 (IL-8) has been revealed as a critical regulator of CNS function and development with participation in many CNS disorders including gliomas.Several promising approaches that target directly or indirectly IL-8 effects in gliomas are currently in progress while more-in-depth studies are needed to validate its biomarker role and elucidate the underlying molecular mechanisms.

种属	Cynomolgus
表达系统	HEK293 Cells
标签	C-His
蛋白编号	A0A2K5TUL7
别名	GCP/IL-8 protein IV, MDNCF, CXCL8, GCP-1, LUCT, NAF, IL-8, Interleukin-8, MONAP, LYNAP, IL8/NAP1 form I, LECT, NAP-1
蛋白构建	Ala23-Pro100
蛋白纯度	> 95% as determined by Tris-Bis PAGE
分子量	10.12 kDa (predicted). Due to glycosylation, the protein migrates to 12-14 kDa based on Tris-Bis PAGE result.

内毒素	< 1 EU/μg by the LAL method.
缓冲液	Supplied as 0.22 μm filtered solution in PBS (pH 7.4).
存储	It is recommended to store the product under sterile conditions at -70°C or lower. Samples are stable for up to 12 months at -80°C. Please avoid multiple freeze-thaw cycles and store products in aliquots.
运输方式	In general, Lyophilized powders are shipping with blue ice. Solutions are shipping with dry ice.
研究背景	Interleukin-8 (IL-8) has been revealed as a critical regulator of CNS function and development with participation in many CNS disorders including gliomas.Several promising approaches that target directly or indirectly IL-8 effects in gliomas are currently in progress while more-in-depth studies are needed to validate its biomarker role and elucidate the underlying molecular mechanisms.